Pano Therapeutics — CNS-Optimized Biguanides for Neurodevelopmental Disorders
Pano Therapeutics is a preclinical-stage biotechnology company developing CNS-optimized biguanides for neurodevelopmental disorders. The company’s lead candidate, PAN1195, is being advanced toward clinical development in Fragile X Syndrome, with planned expansion in Phelan-McDermid Syndrome and Tuberous Sclerosis Complex and a follow-on novel molecule for future non-orphan CNS indications.
What PAN1195 is. PAN1195 is an orally administered, once-daily small molecule from Pano’s novel biguanide platform. It is being developed as a CNS-optimized biguanide intended to redirect a clinically validated pharmacology class into the brain through transporter-guided design, improved tissue exposure, and a once-daily oral pharmacokinetic profile.
Why the biology matters
In Fragile X Syndrome, loss of the FMRP protein leads to dysregulated synaptic translation through hyperactivation of the ERK–mTOR–eIF4E pathway, producing the circuit-level disease biology seen in patients. Biguanide pharmacology converges on this same translation-control axis: through partial inhibition of mitochondrial Complex I and indirect AMPK activation, biguanides act upstream of mTORC1 / ERK / eIF4E and have been shown in published preclinical work to normalize ERK signaling, eIF4E phosphorylation, and FXS-relevant downstream targets including MMP-9. This places biguanide pharmacology mechanistically upstream of the most direct disease-linked node in FXS.
Why CNS optimization matters
Metformin has helped validate the underlying biology, but its clinical utility outside diabetes has been constrained by limited CNS exposure, peak-trough pharmacokinetics, and dependence on renal elimination. Pano’s platform is designed to identify and develop biguanides with improved transporter activity, tissue selectivity, pharmacokinetics, and safety characteristics for CNS use. PAN1195 has been selected from a screen of approximately three hundred novel biguanides profiled across the organic cation transporter, MATE, and PMAT families.
Lead indication: Fragile X Syndrome
Fragile X Syndrome is Pano’s lead indication because it combines strong disease biology fit, clear unmet need, objective readout potential, and attractive orphan-development economics. It also offers an unusually relevant class precedent through metformin, which has generated both preclinical rescue and randomized clinical signals in FXS.
Biomarker-driven development. Pano is pursuing a biomarker-driven development strategy intended to connect preclinical biology with early clinical target engagement. Cross-species quantitative EEG, alongside molecular pharmacodynamic readouts, is being designed to support dose selection, early go / no-go decisions, and a capital-efficient path from healthy volunteers into patients. Objective neurophysiology is positioned as a development advantage and a translational strength, not as a stand-alone efficacy endpoint.
Pipeline expansion
The same platform logic creates follow-on opportunities in other syndromic neurodevelopmental disorders, including Phelan-McDermid Syndrome and Tuberous Sclerosis Complex. These indications share meaningful overlap in translation control, circuit biology, and objective neurophysiological readouts, providing a coherent expansion framework rather than a collection of unrelated programs. A follow-on novel molecule is intended to extend the platform into higher-prevalence non-orphan CNS opportunities over time.
IP and lifecycle strategy
Pano’s intellectual property strategy is built in three layers. The parent compound is covered by an issued U.S. composition-of-matter patent and is being developed for orphan indications, where regulatory exclusivities provide additional market protection. Methods-sharpening filings are planned internationally to extend protection of the parent-compound program. A separate, follow-on molecule, for which international composition-of-matter protection is planned, is intended to support development in higher-prevalence non-orphan CNS opportunities. Together, these layers are designed to support durable, multi-jurisdiction protection across the major pharmaceutical markets.
Pano is building a focused neurodevelopmental-disorders company around a differentiated CNS small-molecule platform, a lead program in Fragile X Syndrome, and a translational development strategy intended to support efficient clinical learning and disciplined portfolio expansion.